• Nem Talált Eredményt

18 eredmény a kulcsszóra: 'triple negative breast cancer'

Coumarin-Based Triapine Derivatives and Their Copper(II) Complexes: Synthesis, Cytotoxicity and mR2 RNR

The prepared copper(II) complexes and their metal-free ligands revealed antiproliferative activity against highly resistant cancer cell lines, including triple negative breast

Protected

N/A

24
0
0
2022
Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis

10.3390/cancers13225694/s1, Table S1: Summary of reported cases of acinic cell carcinomas (ACC) without consideration of the grade or purity, Table S2: Literature review of

Protected

N/A

23
0
0
2022
Theprognosticsignificanceoftumour–stromaratioinoestrogenreceptor-positivebreastcancer SHORTCOMMUNICATION

Conclusions: High stromal content was related to better survival in ER-positive breast cancers across both genders, contrasting data in triple-negative breast cancer and

Protected

N/A

4
0
0
2022
Morphological and pathological response in primary systemic therapy of patients with breast cancer and the prediction of disease free survival: a single center observational study

oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer.. The triple negative paradox:

Protected

N/A

9
0
0
2022
Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2

Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia

Protected

N/A

7
0
0
2022
Immunterápiás lehetőségek és eredmények emlődaganatban

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Adams S, Loi S, Toppmeyer D

Protected

N/A

7
0
0
2022
Pathology & Oncology Research 2018;9:259-267. (

Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes. Pala EE, Bayol Ü, Cumurcu S, et al. Immunohistochemical characteristics of triple

Protected

N/A

21
0
0
2022
Protoflavone-Chalcone Hybrids Exhibit Enhanced Antitumor Action through Modulating Redox Balance, Depolarizing the Mitochondrial Membrane, and Inhibiting ATR-Dependent Signaling

The MCF-7 cell line was used as a representative model for estrogen receptor (ER)-positive breast cancer, while the MDA-MB-231 cell line was used as a model of triple-negative

Protected

N/A

18
0
0
2022
Desensitization of Capsaicin- Sensitive Afferents Accelerates Early Tumor Growth via Increased Vascular Leakage in a Murine Model of Triple Negative Breast Cancer

In this study, we aimed to characterize the role of capsaicin- sensitive fi bers in a mouse model of an orthotopically implanted, triple negative 4T1 breast cancer model,

Protected

N/A

13
0
0
2022
Avelumab, an anti‑PD‑L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

Emens L, Braiteh F, Cassier P et al (2015) Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Schmid P,

Protected

N/A

16
0
0
2022
A humán H1975 tüdő- és MDA-MB-231 emlőadenokarcinóma-sejtes modellek egysejt-tömegcitometriás összehasonlító elemzése

Our aim was to study female-derived human H1975 lung and MDA-MB-231 triple-negative breast cancer ade- nocarcinoma cell line models using single cell mass cytom- etry.. Nine

Protected

N/A

10
0
0
2022
Flavonoid, stilbene and diarylheptanoid constituents of Persicaria maculosa Gray and cytotoxic activity of the isolated compounds

The cytotoxicity assays of selected com- pounds (1–5, 7 and 9–11) on tumorigenic 4 T1 mouse triple negative breast cancer and non-tumorigenic D3 human brain endothelial cells

Protected

N/A

6
0
0
2022
Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study

Swisher SK, Wu Y, Castaneda CA, Lyons GR, Yang F, Tapia C et al (2016) Interobserver agreement between pathologists assess- ing tumor-infiltrating lymphocytes (TILs) in breast

Protected

N/A

9
0
0
2022
New challenges in complex breast cancer diagnostics

2.4Are there any differences in overall diagnostic score, mammography, breast density, radiomorphology, ultrasound, palpation and cytology results of the triple negative and the

Protected

N/A

21
0
0
2023
Bevesszük a kanyart?
[Csath Magdolna: Bevesszük a kanyart? – Tudás-Érték-Jövő. Kairosz Kiadó, 2019, 231 oldal]

Ezeket (az alkalmazhatóság statisztikai módszerekkel történő vizsgálata után) használhatjuk a gazdasági szerkezet átalakulásának nyomon követésére, ugyanakkor ebben az

Protected

N/A

3
0
0
2022
ÖSSZEFOGLALÓ REFERÁTUMOK

tis in early breast cancer patients: effects of systemic treatments. és mtsai: Conformal adjuvant radiotherapy in breast cancer. és mtsa: Specialisation and breast

Protected

N/A

6
0
0
2022
Selectingfirst-linebevacizumab-containingtherapyforadvancedbreastcancer:TURANDOTriskfactoranalyses FULLPAPER

Central European Cooperative Oncology Group (2013) Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast

Protected

N/A

7
0
0
2022
ARTICLE IN PRESS

La base del VI rotó en sentido antihorario, mientras la rotación apical ocurrió en el sentido de las agujas del reloj, sugiriendo una inversión de la mecá- nica rotacional del VI

Protected

N/A

4
0
0
2022

Töltsön fel további dokumentumokat, és töltse le azonnal az anyagtanulmányokat!